GenSight Biologics Reports Interim Financial Results for the First Half of 2017

Publication of the securities note having obtained visa no. 17-297 of the AMF in connection with the capital increase of GenSight Biologics

GenSight Biologics successfully raises €22.5 million from leading investors in the US and Europe

GenSight Biologics launches a capital increase of approximately €20 million

GenSight Biologics reports long-term positive safety and visual acuity results at Week 96 in Phase I/II Study of GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)

GenSight Biologics to Present Data on GS010 and GS030 at the Annual Meeting of ARVO

GenSight Biologics Appoints Mohamed Genead as Chief Medical Officer

GenSight Biologics Announces the Filing of its 2016 Registration Document

GenSight Biologics to Present GS010 at the 4th Annual Retinal Cell & Gene Therapy Innovation Summit

GenSight Biologics to Present GS010 at the 2017 Annual Meeting of the American Academy of Neurology